
NASDAQHealthcareBiotechnology
最新データ
$39.29
−$0.57 · -1.43%
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
前日終値
$39.29
−$0.57 · -1.43%
日中の時刻はETです。市場データは遅延する場合があります。
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $39.29
52週レンジ
現在 $39.29
日中の時刻はETです。市場データは遅延する場合があります。
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $39.29
52週レンジ
現在 $39.29
| 指標(USD) | 2025年度 |
|---|---|
| 研究開発 | 5963.2万 USD |
| 販売・一般管理 | 1048.7万 USD |
| 営業費用 | 7011.9万 USD |
| 受取利息 | 197.4万 USD |
| 減価償却費と償却費 | 30.4万 USD |
| 営業利益 | −7011.9万 USD |
| 純利益 | −6391.3万 USD |
会社概要が更新されました 2026年11月22日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$54.50
上昇余地(38.71%)この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI2103.52万0.22%96.36億 USD0.35%$140.18-2.73%
iShares Russell 2000 ETFIWM2099.22万0.03%715.37億 USD0.19%$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI1897.52万0.00%6893億 USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF836万0.01%302億 USD0.05%$211.44-3.21%
Vanguard Russell 2000 ETFVTWO482.78万0.03%168億 USD0.06%$103.76-2.76%
iShares Russell 2000 Growth ETFIWO449.01万0.03%127.32億 USD0.24%$320.43-3.57%
Schwab U.S. Small-Cap ETFSCHA371.38万0.02%204.47億 USD0.03%$30.51-2.83%
iShares Russell 2000 Value ETFIWN297.2万0.02%130.46億 USD0.24%$198.84-2.08%
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
Vanguard Russell 2000 ETFVTWO
iShares Russell 2000 Growth ETFIWO
Schwab U.S. Small-Cap ETFSCHA
iShares Russell 2000 Value ETFIWNAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。